Kornimate/medical-research-clean huggingface dataset:
effect of inhaled nitric oxide in acute chest syndrome (inosta study)

Conditions: Sickle Cell Disease; Acute Chest Syndrome

Summary: acute chest syndrome (acs) is a frequent and potentially life-threatening pulmonary illness. it is a complication of sickle cell disease and is the leading cause of death from this disease in adults. several pathologic processes are recognized causes of acs, including infectious diseases, hypoventilation secondary to chest pain, in situ thrombosis and pulmonary fat embolism. inhaled nitric oxide (ino) has been shown to be a pulmonary vasodilatator with minimal systemic effects and has also been shown to improve gas exchange in both animal and human acute lung injury (ali). the combined effects of ino gas of improving pulmonary ventilation to perfusion matching, reducing alveolar and systemic inflammation, modulate the course of acute chest syndrome, which combine the physiopathology of vaso-occlusive crisis and acute lung injury. we hypothesise inhaled no will improve oxygenation and clinical outcome of sickle cell disease patients with acute chest syndrome.

objectives: to compare the outcome and duration of acute chest syndrome (acs) in patients with sickle cell disease (scd) treated with ino to that of similar episodes experienced by patients which receive a placebo. study design: bi-center, prospective, randomized, controlled clinical trial * enrollment: 24 months * patients will be treated for 72 hours * patients will be followed for 15 days or until discharged home sample size: * the study will accrue a maximum of 240 patients * progress of the trial will be reviewed by an independent data and safety monitoring committee to determine if randomization should stop for safety reasons.

Eligibility criteria:
inclusion criteria: * patients with sickle cell disease (hemoglobin genotypes characterized by standard procedures as homozygous hemoglobin ss, hemoglobin sc, and s beta thalassemia) * diagnosis of acute chest syndrome based on the presence of fever, dyspnea or chest pain, associated with new pulmonary infiltrates on chest x-ray exclusion criteria: * patient has been hospitalised \< 14 days ago * patients presenting with clinically diagnosed bacterial infections * patients who have received an exchange transfusion in the last 30 days or are in a transfusion program. * current pregnancy or lactation * patient who is currently enrolled in any other investigational drug study * previous participation in this study * any of the following medical conditions: * immediate need of ventilatory support wih orotracheal intubation * hemodynamic instability

Keywords: inhaled drug acute lung injury nitric oxide sickle cell
endothelial glycocalyx damage in brain death organ donors

Conditions: Brain Damage Due to Hypoxia; Organ Donors; Organ Transplant Failure or Rejection

Summary: the study aims the assessment of endothelial glycocalyx (eg) degradation in deceased organ donors. there is a lack of organs for the transplantation program. by the description of the eg status, we can open room for organ optimization before transplantation and improve the organ function after transplantation in marginal donors.


Eligibility criteria:
inclusion criteria: * patients in critical condition declared as brain dead by clinical examination exclusion criteria: * n/a
effects of fat emulsions on pnald and oxidative stress in premature infants

Conditions: Preterm Infant

Summary: abnormal liver function or cholestasis is the result of multiple factors, include low birth weight, smaller than gestational age, preterm birth, infection, lipid emulsion (le) in parenteral nutrition (pn), insufficient enteral nutrition (en) etc. most are inevitable, but the les in pn can be selected. so the investigators compare two les, and want to see if the smof le can improve hepatic index in preterm infants.

for preterm infants, especially for very or extremely low birth weight infants, it's impossible to achieve total enteral feeding in short time. so, pn has played an important role to sustain normal life. but, it also has an adverse effect on liver namely parenteral nutrition-associated liver disease (pnald). le(s) in pn has been showed to result in pnald. so changing the type of les has been an ideal solution. two types of lipid emulsions are currently used for pediatric patients: one le(the second generation) is composed of 50% long-chain triacylglycerols (lcts) and 50% medium-chain triacylglycerols (mcts), prepared from soybean oil and coconut oil respectively. a new le (smof) contains 30% lcts, 30% mcts, 25% olive oil, and 15% fish oil. smof is rich in omega-3 polyunsaturated fatty acids which derived from fish oil. it may reduce inflammation in premature infants, prevent or treat cholestasis, and reduce oxidative stress. because of the different compositions, they have different effect on liver, inflammation, oxidative stress, etc. therefore, the investigators designed a prospective, randomized and double-blind study to compare the different les (mcts/lcts and smof), so as to select a more suitable fat emulsion for premature infants in order to improve clinical outcomes.

Eligibility criteria:
inclusion criteria: * premature infants (gestational age \< 32 weeks) with birth weight \< 1500g were admitted to nicu of xin hua hospital, school of medicine, shanghai jiao tong university, shanghai, china within 24 hours after birth * no contraindications to parenteral nutrition * expected pn support for 14 days or more * parents or guardians agree exclusion criteria: * parenteral nutrition support was provided prior to enrollment * en calorie for 10% or more * congenital intestinal structural/functional abnormalities * liver function damage caused by viral hepatitis, genetic metabolism and abnormal biliary tract * congenital or acquired immunodeficiency * complex congenital heart disease

Keywords: parenteral nutrition lipid emulsion smof pnald oxidative stress
to assess breathing exercise as a relaxation method

Conditions: Dental Anxiety

Summary: in this study investigator evaluate the effectiveness of breathing exercise using two different play toys in reducing dental anxiety.

bubble blower and pin wheel are used to facilitate breathing exercise and to reduce dental anxiety hence more cooperation of participants during dental treatment

Eligibility criteria:
inclusion criteria: * children that had been introduced to dental setting without receiving any dental treatment * according to corah 's dental anxiety scale children classified with score 19 or more * no learning disability or psychological disorder or parental anxiety exclusion criteria: * children in emergency visit * allergy to anesthetic drugs * use of analgesic before treatment * teeth with necrotic pulp * children whose parents refused to sign informed consent

Keywords: breathing exercise play toys heart rate venham picture test salivary alpha amylase
dexamethasone for migraine - dose comparison

Conditions: Migraine

Summary: dexamethasone is an evidence-based treatment of acute migraine. this is a randomized comparison of two different doses of dexamethasone for acute migraine. all patients will also be treated with metoclopramide.

investigational medications. medications in each study arm are as follows: a. metoclopramide 10mg iv drip over 15 minutes (for acute treatment)+ dexamethasone 4 mg iv b. metoclopramide 10mg iv drip over 15 minutes (for acute treatment)+ dexamethasone 16 mg iv assignment. will be concealed. the research pharmacist will determine assignment based on a random number sequence. randomization. randomization will occur in blocks of 4 based on a random number generator. blinding. patients, clinicians, and research personnel will be blinded. stratification. subjects will be stratified by study site (moses or weiler) and baseline pain intensity (moderate or severe). follow-up phone calls will be performed 48 hours and 7 days after ed (emergency department) discharge. at the first call, the next follow-up phone call will be scheduled. attempts to complete the follow-up calls successfully will be made every eight hours until deemed futile. at this point, questionnaires will be sent by express courier, and failing this, the investigator will perform a home visit. at the 48-hour phone call, the focus will be assessments of pain, functional status, migraine associated features, adverse events, satisfaction with the medication received, and use of rescue medication. the focus of the seven day phone call will be on the total number of days with headache since ed discharge, the need for repeat ed visits, healthcare providers visited, days of work missed, and adverse medication effects.

Eligibility criteria:
inclusion criteria: * moderate or severe migraine exclusion criteria: * medication contra-indication * concern for secondary cause of headache
the effectiveness of arthroscopic cartilage regeneration facilitating procedure for patients with knee osteoarthritis

Conditions: Osteoarthritis of Knees

Summary: the aim of this study is to discuss the effect of gait pattern in patients receiving arthroscopic cartilage regeneration facilitating procedure (acrfp) for treatment of osteoarthritis of knees.

pain during gait is the most common and problematic symptom in individuals with osteoarthritis (oa) of knee joints. limited range of motion, reduced walking speed, and a shortened stride length are also occasionally observed. these changes may be secondary or compensatory phenomena adopted by individuals to lessen the load on the oa-affected knees. it is generally agreed that medial plica can produce symptoms in the knee joint, and can be successfully treated by arthroscopic resection when it becomes inflamed, thickened, and fibrotic. in 2006, lyu and hsu reported that medial plica had strong correlation with medial compartment osteoarthritis of knees. in their further studies disclosing the kinematic relationship of the medial plica with the medial femoral condyle found that medial plica might cause some degree of abrasion on the surface of medial femoral condyle during knee motion. the repeated injuries elicited by this abrasion phenomenon might trigger some inflammatory process to gradually damage the cartilage of knee. based on these findings, lyu developed a concept of arthroscopic cartilage regeneration facilitating procedure (acrfp) by arthroscopic resection of the medial plica, in addition to both medial and lateral capsular release, for the treatment of osteoarthritis of the knee joint. the clinical outcome of this procedure by eradication of the abrasion phenomenon caused by the tight, fibrotic, and hypertrophied medial plica, with decompression of the patellofemoral joint, the pain in most patients could be reduced, and the degenerative process in the medial compartment of some patients might be decelerated or arrested. during the acrfp, additional procedures such as synovectomy, abrasiochondroplasty, or partial menisectomy may also be carried out when necessary. it has been found that the elimination of the existing detrimental factors may provide a preferable environment for regeneration of the damaged cartilage. although the results of acrfp for treatment of osteoarthritis of knee has been supported by several researches as being an effective method, it still lacks investigations on the gait pattern after such procedure. therefore, the aim of this study is to discuss the effectiveness of the acrfp for the patients with osteoarthritis of knee joints, specifically focused on their gait pattern.

Eligibility criteria:
inclusion criteria: * patients between the ages 20 and 85 who will receive acrfp for treatment of osteoarthritis in the knee joints exclusion criteria: * patients with walking disability

Keywords: osteoarthritis of knees arthroscopic cartilage regeneration facilitating procedure (acrfp) foot pressure gait
friendship bench for women who use methamphetamine in vietnam

Conditions: Methamphetamine Use; Common Mental Disorders (CMD)

Summary: the high comorbidity of mental health issues and meth use in women worsens both their mental health and meth use outcomes. the study team proposes to evaluate the potential of friendship bench to be used as a low-threshold, task-shifting mental health intervention among women who use methamphetamine in vietnam - a lower-middle-income country. the study will provide preliminary data for a r01 trial testing the effectiveness friendship bench to improve mental health and methamphetamine use outcomes among women who use methamphetamine in vietnam.

the specific aims of this research proposal are to: (1) assess the mental health needs of wwum in haiphong, (2) adapt friendship bench to the specific needs of vietnamese wwum and (3) assess the feasibility, fidelity, and acceptability of the adapted friendship bench for common mental disorders among wwum and preliminary indicators of its impact in improving their mental health and methamphetamine use in a two-arm randomized trial, comparing friendship bench with usual psychiatric care.

Eligibility criteria:
inclusion criteria: * adult women (\>=18 years old) * moderate or greater risk for meth use (assist ≥ 4) * moderate or greater cmd symptom severity (depression ≥ 10, anxiety ≥ 8, and/or stress ≥ 15 on dass-21) exclusion criteria: * severe psychotic disorders or other interfering problems that require specialty care; * inability to understand study procedures by the research team's judgment.

Keywords: methamphetamine women who use drugs common mental disorders friendship bench lay worker-delivered intervention
the effect of using a kaleidoscope during central venous catheter dressing changes in children with cancer

Conditions: Pain; Anxiety

Summary: many medical interventions, including the dressing of central venous catheters, a common procedure used for children with cancer, cause anxiety and pain in children. this can adversely affect their care and recovery. this study aims to determine the effect of using a kaleidoscope during central venous catheter dressing on anxiety and pain in children with cancer.

this was a randomised controlled trial with 60 children aged 6-12 diagnosed with cancer who were placed either in a kaleidoscope group (n=30) or a control group (n=30). each child's anxiety was evaluated by the child using the child fear scale before, during and after a central venous catheter dressing procedure, and each child's pain during and after the procedure was evaluated by the child using the wong-baker faces pain rating scale (wb-faces). each child's heart rate and oxygen saturation were measured with a pulse oximeter device before, during and after central venous catheter dressing. the children in kaleidoscope group looked into the kaleidoscope and slowly turned it. this distraction procedure began immediately before the central venous catheter dressing and continued until it was finished. no intervention was performed to reduce pain and anxiety for children in the control group. parents accompanied their children during the procedure in both groups.

Eligibility criteria:
inclusion criteria: * a cancer diagnosis, * having a central venous catheter, * 6-12 years old, * not having taken any analgesics in the 6 hours before the central venous catheter dressing, -being in a non-terminal phase of the disease, * absence of neutropenia, * volunteering to participate in the study, * the absence of any health problems that prevent communication in the parent or the child. exclusion criteria: -the reporting of pain for another reason at the time of the central venous catheter dressing.

Keywords: anxiety cancer central venous catheter child pain
the treatment of hypertension associated with severe preeclampsia (pe). a trial of urapidil versus nicardipine

Conditions: Hypertension; Preeclampsia

Summary: the objective of this study is to demonstrate that urapidil is not inferior to nicardipine for the treatment of hypertension associated with preeclampsia (pe) and that it is better tolerated. * efficacy endpoint : mean arterial blood pressure corrected to 100-120 mmhg after 120 min of study drug administration. * safety endpoints : clinical and biological observation for any side effect. all infants will be observed in the neonatology unit (during 48h). pharmacokinetic study included to study : * transplacental transfer, * transfer in breast milk, * and neonatal elimination (premature babies of mothers treated with urapidil (less than 33 wg))


Eligibility criteria:
inclusion criteria: * adult patients * singleton pregnancy * patients with remaining hypertension despite an oral treatment for who an iv antihypertensive treatment is indicated patient with pe, as defined by : * systolic blood pressure (bp) ≥ 140 mmhg and/or diastolic bp ≥ 90 mmhg, after the 20th week of amenorrhea, without chronic hypertension, and * proteinuria \> 300 mg.day-1 or \> 2 crosses(++) on an urinary dipstick, or patient with severe pregnancy induced hypertension (pih), as defined by : systolic bp ≥ 160 mmhg and/or diastolic bp ≥110 mmhg, after the 20th week of amenorrhea, without chronic hypertension, * written informed consent signed and dated by both investigator and patient, * valid social security affiliation exclusion criteria: * known allergy to study drugs * contra-indication to the study drugs: stenosis of the aortic isthmus, arteriovenous shunt, coarctation of the aorta, unstable angina, compensatory hypertension, myocardial infarction \< 8 days. * eclampsia * person with difficulty understanding information * person with diminished responsibility, * ongoing intravenous antihypertensive treatment, * no pressure cuff adapted to the morphology of the arms of the patients * concomitant use of 5 phosphodiesterase inhibitors * participation in a clinical trial within 6 months prior to inclusion

Keywords: pre-eclampsia urapidil nicardipine
acc - atrial contribution to crt

Conditions: Dilated Cardiomyopathy

Summary: this prospective study will evaluate in patients, fulfilling implant criteria for cardiac resynchronisation therapy (crt) implant, the optimal atrial contribution to the resynchronised ventricles in the event of right atrial pacing.

all patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. av-delay optimization will be performed using aortic vti measured by continuous wave doppler in a modified 4-chamber view. during optimisation aortic vti will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (ihr).

Eligibility criteria:
inclusion criteria: * symptoms of heart failure * left ventricular dysfunction * ventricular dyssynchrony * 18 years or of legal age in order to give informed consent according to national laws * able to understand the nature of the procedure * available for follow-up on a regular basis at an approved investigational center exclusion criteria: * atrial fibrillation * life expectancy of less than six months due to other medical conditions * for women: pregnancy or absence of medically accepted birth control * inability or refusal to sign the patient informed consent * inability or refusal to comply with the follow up schedule or protocol requirements * inability to undergo device implant, including general anaesthesia if required * mechanical tricuspid prosthesis * currently enrolled in another investigational study, including drug investigations * hypertrophic obstructive cardiomyopathy (hocm) * not meeting the inclusion criteria
tacrolimus treatment of patients with idiopathic membranous nephropathy

Conditions: Idiopathic Membranous Nephropathy

Summary: the purpose of this study is: * to explore the potential role of tacrolimus in the treatment of membranous nephropathy. * to investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.

idiopathic membranous nephropathy is the most common cause of nephrotic syndrome in adults. over the past decade, a number of studies have reported therapeutic efficacy for treatment with cyclosporine-a (csa) in patients with nephrotic syndrome including patients with membranous nephropathy. this study will evaluate the safety and effectiveness of a new calcineurin immunosuppressive drug, tacrolimus (fk506), in reducing the amount of protein in the urine in patients with membranous nephropathy. forty patients with biopsy-proven membranous nephropathy will be recruited. candidates must have completed at least six month of treatment with a stable dose of angiotensin converting enzyme (ace) inhibitors or angiotensin receptor blockers (arbs). they will be screened with a medical history, physical examination, blood tests, and an examination for infection, cancers, and other conditions that can cause membranous nephropathy. the investigators plan to conduct an open-label study of the efficacy and safety of tacrolimus in the treatment of membranous nephropathy. they will be treated with oral tacrolimus for 6 months, followed by 6 months of maintenance. proteinuria, renal function will be monitored. complete remission is defined as 24-hour urinary protein excretion to less than 0.4 mg/day. this study will explore the potential role of tacrolimus in the treatment of membranous nephropathy, which is usually resistant to conventional therapy.

Eligibility criteria:
inclusion criteria: * biopsy-proven idiopathic membranous nephropathy * nephrotic syndrome with proteinuria ( \> 4 g/day) and serum albumin \< 30 g/dl * age 18-60 years with informed consent exclusion criteria: * patient with abnormal liver function tests * prior therapy with sirolimus, csa, mmf, or azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days * active/serious infection * patient with hepatitis b surface antigen or who is hepatitis c antibody positive * patient who is diabetic * patient is allergic or intolerant to macrolide antibiotics or tacrolimus

Keywords: idiopathic membranous nephropathy treatment tacrolimus cyclophosphamide
study of the evolution of the expression of the lamp-2 protein during the advance in age

Conditions: Aging

Summary: recruitment on the rav pole in consultation or day hospital. competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1.

recruitment on the rav pole in consultation or day hospital. competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1. after explanations and collection consent, collection of the patient's socio-demographic and medical characteristics and then carrying out a peripheral venous blood sample (2 x 5ml tubes).

Eligibility criteria:
inclusion criteria: * men and women over 60 years of age. exclusion criteria: * inability to understand consent, * non-security beneficiaries * social, subjects protected by law, subjects deprived of liberty, * history of breast cancer, * brain tumor, * melanoma, * colon cancer, * lung cancer, * prostate cancer, * lymphoma, * myeloma, * syndrome myelodysplastic/myeloproliferative, * leukemia, * history of radiation therapy.